^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Viracept (nelfinavir)

    i
    Company:
    Roche, ViiV Healthcare
    Drug class:
    AKT inhibitor, Protease inhibitor
    Related drugs:
    Apply
    Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 (SCALOP-2) (NCT02024009)
    Phase 1/2
    University of Oxford
    Completed
    Last update posted :
    07/25/2024
    Initiation :
    03/01/2016
    Primary completion :
    06/23/2021
    Completion :
    06/23/2021
    KRAS
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • Viracept (nelfinavir)
    Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer (SAKK 65/08) (NCT01164709)
    Phase 1
    Swiss Group for Clinical Cancer Research
    Completed
    Last update posted :
    05/15/2019
    Initiation :
    07/01/2010
    Primary completion :
    07/01/2012
    Completion :
    11/01/2013
    ALK • TNFRSF8
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    bortezomib • Viracept (nelfinavir)
    Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors (NCT00436735)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    10/06/2017
    Initiation :
    09/01/2006
    CYP3A4
    |
    Viracept (nelfinavir) • midazolam hydrochloride